Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BCYC
stocks logo

BCYC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
7.08M
+90.83%
-0.942
+15.67%
7.25M
-27.38%
-0.817
-7.2%
5.76M
+97.36%
-0.903
-20.76%
Estimates Revision
The market is revising Upward the revenue expectations for Bicycle Therapeutics plc (BCYC) for FY2025, with the revenue forecasts being adjusted by 9.68% over the past three months. During the same period, the stock price has changed by -0.28%.
Revenue Estimates for FY2025
Revise Upward
up Image
+9.68%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.29%
In Past 3 Month
Stock Price
Go Down
down Image
-0.28%
In Past 3 Month
Wall Street analysts forecast BCYC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCYC is 22.29 USD with a low forecast of 11.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast BCYC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCYC is 22.29 USD with a low forecast of 11.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 7.140
sliders
Low
11.00
Averages
22.29
High
44.00
Current: 7.140
sliders
Low
11.00
Averages
22.29
High
44.00
Truist
Hold
initiated
$10
2025-11-24
Reason
Truist
Price Target
$10
2025-11-24
initiated
Hold
Reason
Truist initiated coverage of Bicycle Therapeutics with a Hold rating and $10 price target. The time to market and ultimate market potential remains uncertain for Zele, pending further visibility from the Phase 2/3 Duravelo-2 trial, particularly as Padcev continues to entrench as a widely adopted standard of care, the analyst tells investors in a research note. Truist adds that it sees broader value from Bicycle's pipeline, including BT5528, and the radiopharma franchise, though these programs remain early in development and are unlikely to yield meaningful near-term contribution.
RBC Capital
Leonid Timashev
Outperform -> Sector Perform
downgrade
$27 -> $11
2025-10-31
Reason
RBC Capital
Leonid Timashev
Price Target
$27 -> $11
2025-10-31
downgrade
Outperform -> Sector Perform
Reason
RBC Capital analyst Leonid Timashev last night downgraded Bicycle Therapeutics to Sector Perform from Outperform with a price target of $11, down from $27, following the Q3 report. The company's pipeline programs are taking more time to reach inflection points, the analyst tells investors in a research note. RBC thinks Bicycle's near-term updates may not provide substantial enough data to de-risk its programs and drive share upside. As such, the firm moves to the sidelines pending greater visibility into the path forward for zelenectide and BT5528.
Citizens JMP
Reni Benjamin
Outperform
maintain
$10 -> $12
2025-10-31
Reason
Citizens JMP
Reni Benjamin
Price Target
$10 -> $12
2025-10-31
maintain
Outperform
Reason
Citizens JMP analyst Reni Benjamin raised the firm's price target on Bicycle Therapeutics to $12 from $10 and keeps an Outperform rating on the shares. Bicycle reported Q3 financial results and updated corporate milestones, including regulatory feedback regarding dose selection for the pivotal Duravelo-2 now expected in 1Q26, the analyst tells investors in a research note. Bicycle shares have upside from current levels, with the zele pivotal trial enrolling, multiple partnerships secured, and a strong cash position of $648.3M, the firm says.
RBC Capital
Leonid Timashev
Outperform -> Sector Perform
downgrade
$27 -> $11
2025-10-30
Reason
RBC Capital
Leonid Timashev
Price Target
$27 -> $11
2025-10-30
downgrade
Outperform -> Sector Perform
Reason
RBC Capital analyst Leonid Timashev downgraded Bicycle Therapeutics to Sector Perform from Outperform with a price target of $11, down from $27.
Citizens JMP
Outperform
to
NULL
downgrade
$22 -> $10
2025-08-12
Reason
Citizens JMP
Price Target
$22 -> $10
2025-08-12
downgrade
Outperform
to
NULL
Reason
Citizens JMP lowered the firm's price target on Bicycle Therapeutics to $10 from $22 and keeps an Outperform rating on the shares. Bicycle recently reported Q2 financial results and updated corporate milestones, and Citizens believes that the main value-driving event for this year is the selection of the optimal go-forward dose of zelenectide pevedotin in the pivotal Duravelo-2 trial. Bicycle shares may still provide upside from current levels, the analyst tells investors in a research note.
Oppenheimer
Jay Olson
Outperform
to
Outperform
downgrade
$48 -> $44
2025-08-11
Reason
Oppenheimer
Jay Olson
Price Target
$48 -> $44
2025-08-11
downgrade
Outperform
to
Outperform
Reason
Oppenheimer analyst Jay Olson lowered the firm's price target on Bicycle Therapeutics to $44 from $48 and keeps an Outperform rating on the shares. The firm notes the company reported Q2 financial results with $2.9M collaboration revenue, $71.0M R&D and $18.5M G&A expenses, and $721.5M cash. A notable update was the announcement of cost-reduction initiatives aimed at lowering operating costs by 30%, mostly through a 25% workforce reduction, which will further extend the financial runway into 2028. Oppenheimer views the cost-reduction initiative as a prudent measure to sharpen focus on near-term priorities, particularly the upcoming zelenectide pevedotin Phase 2/3 Duravelo-2 dose selection updates in Q4.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bicycle Therapeutics PLC (BCYC.O) is -2.07, compared to its 5-year average forward P/E of -6.81. For a more detailed relative valuation and DCF analysis to assess Bicycle Therapeutics PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.81
Current PE
-2.07
Overvalued PE
-2.51
Undervalued PE
-11.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.27
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.35
Undervalued EV/EBITDA
-8.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
42.28
Current PS
0.00
Overvalued PS
67.55
Undervalued PS
17.02
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BCYC News & Events

Events Timeline

(ET)
2025-10-30
07:49:31
Bicycle Therapeutics announces Q3 earnings per share of 85 cents, below consensus estimate of $1.07.
select
2025-08-08 (ET)
2025-08-08
07:08:54
Bicycle Therapeutics reports Q2 EPS ($1.14), consensus (93c)
select
2025-05-01 (ET)
2025-05-01
07:38:25
Bicycle Therapeutics reports Q1 EPS (88c), consensus (81c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
11-20PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC

  • Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Bicycle Therapeutics plc and its executives, urging affected investors to reach out for assistance.

  • Analyst Downgrade: RBC Capital Markets analyst Leonid Timashev downgraded Bicycle's stock from Outperform to Sector Perform due to delays in the development of its cancer treatment, which may negatively impact its market position against competitors.

  • Stock Price Impact: Following the downgrade, Bicycle's American Depositary Receipt (ADR) price dropped by 7.88%, closing at $8.07 on October 31, 2025.

  • Pomerantz LLP Background: Pomerantz LLP is a well-established law firm specializing in corporate, securities, and antitrust class litigation, with a history of advocating for victims of securities fraud and achieving significant damages awards.

[object Object]
Preview
4.0
11-01NASDAQ.COM
Citizens Upholds Outperform Rating for Bicycle Therapeutics plc - Depositary Receipt (BCYC) Market

  • Analyst Recommendation: Citizens maintains a Market Outperform recommendation for Bicycle Therapeutics plc - Depositary Receipt (NasdaqGS:BCYC) as of October 31, 2025, with a projected one-year price target of $24.91/share, indicating a potential upside of 209.00% from its current price of $8.06/share.

  • Projected Revenue and EPS: The projected annual revenue for Bicycle Therapeutics is estimated at $48 million, reflecting a 146.60% increase, while the projected non-GAAP EPS is -4.30.

  • Fund Sentiment: There are 142 funds reporting positions in Bicycle Therapeutics, with a 10.94% increase in ownership over the last quarter. The average portfolio weight for these funds is 0.24%, which has increased by 18.04%.

  • Shareholder Activity: Notable shareholders include Baker Bros. Advisors, Fcpm Iii Services B.v., Armistice Capital, Westfield Capital Management Co, and Siren, L.L.C., with varying changes in their shareholdings and portfolio allocations over the last quarter.

[object Object]
Preview
6.0
10-31Benzinga
Citizens Upgrades Bicycle Therapeutics to Market Outperform and Increases Price Target to $12

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences to improve their market performance.

  • Market Winning Tools: The platform provides tools and resources designed to help traders win in the markets every day.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bicycle Therapeutics PLC (BCYC) stock price today?

The current price of BCYC is 7.14 USD — it has increased 0 % in the last trading day.

arrow icon

What is Bicycle Therapeutics PLC (BCYC)'s business?

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.

arrow icon

What is the price predicton of BCYC Stock?

Wall Street analysts forecast BCYC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCYC is 22.29 USD with a low forecast of 11.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bicycle Therapeutics PLC (BCYC)'s revenue for the last quarter?

Bicycle Therapeutics PLC revenue for the last quarter amounts to 11.73M USD, increased 338.49 % YoY.

arrow icon

What is Bicycle Therapeutics PLC (BCYC)'s earnings per share (EPS) for the last quarter?

Bicycle Therapeutics PLC. EPS for the last quarter amounts to -0.85 USD, increased 14.86 % YoY.

arrow icon

What changes have occurred in the market's expectations for Bicycle Therapeutics PLC (BCYC)'s fundamentals?

The market is revising Upward the revenue expectations for Bicycle Therapeutics plc (BCYC) for FY2025, with the revenue forecasts being adjusted by 9.68% over the past three months. During the same period, the stock price has changed by -0.28%.
arrow icon

How many employees does Bicycle Therapeutics PLC (BCYC). have?

Bicycle Therapeutics PLC (BCYC) has 305 emplpoyees as of December 05 2025.

arrow icon

What is Bicycle Therapeutics PLC (BCYC) market cap?

Today BCYC has the market capitalization of 495.29M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free